



## ASX ANNOUNCEMENT

### Actinogen appoints Chief Financial Officer

**Sydney, 29 September 2020.** Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to advise that Jeff Carter has been appointed as the Company's new Chief Financial Officer (CFO). Mr. Carter will commence effective 28 September 2020.

With Actinogen's focus on progressing and expanding its clinical development pipeline, the appointment will allow for more robust, integrated and strategic financial support during this time of preparation, to optimise execution of strategy and an improved capability to then build the business in the future.

Mr. Carter is an experienced ASX-listed company CFO with a broad corporate background and a significant understanding of the biotech sector. He currently holds, and will continue to hold, a part-time position as CFO for Amplia Therapeutics Limited (ASX: ATX). Over the last 20 years Mr Carter has held positions in various biotech companies including CFO, Company Secretary, and ASX Liaison Officer for a dual listed NASDAQ company, where he was part of the senior management team involved in the USA Initial Public Offering of the company. Mr. Carter holds a Bachelor of Financial Administration (UNE) and a Master of Applied Finance (Macquarie University) and is a qualified Chartered Accountant, while also having experience in Investment Banking and M&A which provides additional insight into the corporate world. Prior to his move into the healthcare sector he held senior positions with Coca Cola Amatil, Santos, Canadian Imperial Bank of Commerce and Touche Ross.


Actinogen's financial services have previously been managed by financial accountant, Tanya Woolley. Ms. Woolley will work closely with Jeff to ensure a smooth transition, before ceasing to provide financial services for Actinogen by the end of October. The Actinogen team thanks Ms. Woolley for her hard work and commitment and wishes her all the best in the future.

**Dr. Bill Ketelbey, Actinogen CEO and MD, said:**

*"We are delighted that Jeff is joining Actinogen at this exciting time. The appointment comes as we progress towards our next series of clinical trials, with plans to commence multiple studies in the near-to-medium term. Jeff will be a valuable addition to the team, with strong corporate experience and a proven track record as CFO for other ASX-listed biotech companies with the capability to build and implement strategic approaches in a range of relevant business activities. We look forward to the broader skills and experience he brings to the senior management team."*

**ENDS**

**Actinogen Medical**

Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: bill.ketelbey@actinogen.com.au  
 @BillKetelbey

**Investor Enquiries**

Miranda Newnham  
Vesparum Capital  
P: +61 3 8582 4800  
E: actinogen@vesparum.com

**Announcement authorised by the Board of Directors of Actinogen Medical**

ACTINOGEN MEDICAL LIMITED TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW  
Suite 901, Level 9, 109 Pitt Street, Sydney NSW 2000 AUSTRALIA  
TELEPHONE +61 2 8964 7401  
WEB [www.actinogen.com.au](http://www.actinogen.com.au)

### **About Actinogen Medical**

Actinogen Medical (ASX:ACW) is an ASX-listed biotechnology company developing novel therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

### **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from currently available therapies. It works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and particular behavioural symptoms. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in a number of diseases/disorders, including Alzheimer's disease, schizophrenia, diabetes and other conditions associated with cognitive impairment.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, confirmed the drug's strong safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant improvement in cognition, which, along with other recently generated data, confirms 11β-HSD1 inhibition by Xanamem as a promising potential treatment for cognitive impairment and other symptoms associated with raised cortisol.

The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2020/21, including MCI due to Alzheimer's disease.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Xanamem™ is a trademark of Actinogen Medical.

### **Disclaimer**

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**